Reducing hemorrhagic complication by dabigatran via neurovascular protection after recanalization with tissue plasminogen activator in ischemic stroke of rat

Journal of Neuroscience Research

Volumn 92, Issue 1, 2014, Pages 46-53

  Kono, Syoichiro ^a   Deguchi, Kentaro ^a   Omote, Yoshio ^a   Yunoki, Taijun ^a   Yamashita, Toru ^a   Kurata, Tomoko ^a   Ikeda, Yoshio ^a   Abe, Koji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Dabigatran; Hemorrhagic complication; Neurovascular unit; Pericyte; Thrombolysis; TPA

Indexed keywords

ALTEPLASE; CARBOXYMETHYLCELLULOSE; DABIGATRAN; GELATINASE B; THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULANT THERAPY; ARTICLE; ASTROCYTE; BASEMENT MEMBRANE; BLOOD CLOTTING; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FIBRINOLYTIC THERAPY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PARAPLEGIA; PERICYTE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTHROMBIN TIME; RAT; RECANALIZATION; REPERFUSION; RISK ASSESSMENT; TRANSIENT MIDDLE CEREBRAL ARTERY OCCLUSION; ZYMOGRAPHY;

DABIGATRAN; HEMORRHAGIC COMPLICATION; NEUROVASCULAR UNIT; PERICYTE; THROMBOLYSIS; TPA;

ANIMALS; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; INTRACRANIAL HEMORRHAGES; MALE; RATS; RATS, WISTAR; STROKE; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

EID: 84888056988     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23302     Document Type: Article

References (37)

1. Abe K, Kawagoe J, Araki T, Aoki M, Kogure K. 1992. Differential expression of heat shock protein 70 gene between the cortex and caudate after transient focal cerebral ischaemia in rats. Neurol Res 14:381-385.
2. Aschner JL, Lum H, Fletcher PW, Malik AB. 1997. Bradykinin- and thrombin-induced increases in endothelial permeability occur independently of phospholipase C but require protein kinase C activation. J Cell Physiol 173:387-396.
3. Augustin HG, Braun K, Telemenakis I, Modlich U, Kuhn W. 1995. Ovarian angiogenesis. Phenotypic characterization of endothelial cells in a physiological model of blood vessel growth and regression. Am J Pathol 147:339-351.
4. Bamford J, Sandercock P, Dennis M, Warlow C, Jones L, McPherson K, Vessey M, Fowler G, Molyneux A, Hughes T, et al. 1988. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project 1981-86. 1. Methodology, demography and incident cases of first-ever stroke. J Neurol Neurosurg Psychiatry 51:1373-1380.
5. Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. 1996. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 27:373-380.
6. Casado Naranjo I, Portilla-Cuenca JC, Jiménez Caballero PE, Calle Escobar ML, Romero Sevilla RM. 2011. Fatal intracerebral hemorrhage associated with administration of recombinant tissue plasminogen activator in a stroke patient on treatment with dabigatran. Cerebrovasc Dis 32:614-615.
7. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, et al., RE-LY Steering Committee and Investigators. 2009. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139-1151.
8. De Smedt A, De Raedt S, Nieboer K, De Keyser J, Brouns R. 2010. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran. Cerebrovasc Dis 30:533-534.
9. del Zoppo GJ, Mabuchi T. 2003. Cerebral microvessel responses to focal ischemia. J Cereb Blood Flow Metab 23:879-894.
10. Goto H, Fujisawa H, Oka F, Nomura S, Kajiwara K, Kato S, Fujii M, Maekawa T, Suzuki M. 2007. Neurotoxic effects of exogenous recombinant tissue-type plasminogen activator on the normal rat brain. J Neurotrauma 24:745-752.
11. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Höxter G, Mahagne MH, et al. 1995. The European Cooperative Acute Stroke Study (ECASS). Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA 274:1017-1025.
12. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, et al. 1998. Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 352:1245-1251.
13. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, ECASS Investigators . 2008. Thrombolysis with alteplase 3 to 4.5 hr after acute ischemic stroke. N Engl J Med 359:1317-1329.
14. Ishitsuka K, Ago T, Arimura K, Nakamura K, Tokami H, Makihara N Kuroda J, Kamouchi M, Kitazono T. 2012. Neurotrophin production in brain pericytes during hypoxia: a role of pericytes for neuroprotection. Microvasc Res 83:352-359.
15. Kamiya T, Katayama Y, Kashiwagi F, Terashi A. 1993. The role of bradykinin in mediating ischemic brain edema in rats. Stroke 24:571-575; discussion 575-576.
16. Kawai H, Deguchi S, Deguchi K, Yamashita T, Ohta Y, Shang J, Tian F, Zhang X, Liu N, Liu W, et al. 2011. Synergistic benefit of combined amlodipine plus atorvastatin on neuronal damage after stroke in Zucker metabolic rat. Brain Res 1368:317-323.
17. Lee VH, Conners JJ, Prabhakaran S. 2012. Intravenous thrombolysis in a stroke patient taking dabigatran. J Stroke Cerebrovasc Dis 21:916.e11-e12.
18. Maier CM, Hsieh L, Crandall T, Narasimhan P, Chan PH. 2006. Evaluating therapeutic targets for reperfusion-related brain hemorrhage. Ann Neurol 59:929-938.
19. Marrone LC, Marrone AC. 2012. Thrombolysis in an ischemic stroke patient on dabigatran anticoagulation: a case report. Cerebrovasc Dis 34:246-247.
20. Matute MC, Guillán M, García-Caldentey J, Buisan J, Aparicio M, Masjuan J, Alonso de Leciñana M. 2011. Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran. Thromb Haemost 106:178-179.
21. Nakagawara J, Minematsu K, Okada Y, Tanahashi N, Nagahiro S, Mori E, Shinohara Y, Yamaguchi T, J-MARS Investigators . 2010. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice. The Japan Post-Marketing Alteplase Registration Study (J-MARS). Stroke 41:1984-1989.
22. Omori N, Jin G, Li F, Zhang WR, Wang SJ, Hamakawa Y, Nagano I, Manabe Y, Shoji M, Abe K. 2002. Enhanced phosphorylation of PTEN in rat brain after transient middle cerebral artery occlusion. Brain Res 954:317-322.
23. Paxinos G, Watson C. 1982. The rat brain in stereotaxic coordinates. New York: Academic Press.
24. Pfeilschifter W, Bohmann F, Baumgarten P, Mittelbronn M, Pfeilschifter J, Lindhoff-Last E, Steinmetz H, Foerch C. 2012. Thrombolysis with recombinant tissue plasminogen activator under dabigatran anticoagulation in experimental stroke. Ann Neurol 71:624-633.
25. Rosenberg GA. 2002. Matrix metalloproteinases in neuroinflammation. Glia 39:279-291.
26. Sakata T, Kario K, Matsuo T, Katayama Y, Matsuyama T, Kato H, Miyata T. 1995. Suppression of plasma-activated factor VII levels by warfarin therapy. Arterioscler Thromb Vasc Biol 15:241-246.
27. Sangha N, El Khoury R, Misra V, Lopez G. 2012. Acute ischemic stroke treated with intravenous tissue plasminogen activator in a patient taking dabigatran with radiographic evidence of recanalization. J Stroke Cerebrovasc Dis 21:917.e5-e8.
28. Suarez S, Ballmer-Hofer K. 2001. VEGF transiently disrupts gap junctional communication in endothelial cells. J Cell Sci 114:1229-1235.
29. 1995. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581-1587.
30. Toomey JR, Abboud MA, Valocik RE, Koster PF, Burns-Kurtis CL, Pillarisetti K, Danoff TM, Erhardt JA. 2006. A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis. J Thromb Haemost 4:1989-1996.
31. Vadivel K, Bajaj SP. 2012. Structural biology of factor VIIa/tissue factor initiated coagulation. Front Biosci 17:2476-2494.
32. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, SITS-MOST investigators. 2007. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369:275-282.
33. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. 2007. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Thromb Haemost 98:333-338.
34. Wu J, Hua Y, Keep RF, Nakamura T, Hoff JT, Xi G. 2003. Iron and iron-handling proteins in the brain after intracerebral hemorrhage. Stroke 34:2964-2969.
35. Yamashita T, Kamiya T, Deguchi K, Inaba T, Zhang H, Shang J, Miyazaki K, Ohtsuka A, Katayama Y, Abe K. 2009. Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain. J Cereb Blood Flow Metab 29:715-725.
36. Yemisci M, Gursoy-Ozdemir Y, Vural A, Can A, Topalkara K, Dalkara T. 2009. Pericyte contraction induced by oxidative-nitrative stress impairs capillary reflow despite successful opening of an occluded cerebral artery. Nat Med 15:1031-1037.
37. Zhang L, Schallert T, Zhang ZG, Jiang Q, Arniego P, Li Q, Lu M, Chopp M. 2002. A test for detecting long-term sensorimotor dysfunction in the mouse after focal cerebral ischemia. J Neurosci Methods 117:207-214.